HWAM
KNSA icon

Hennion & Walsh Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Hennion & Walsh Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-67,341
Closed -$3.24M – 986
2026
Q1 		$3.24M Sell
67,341
-11,859
-15% -$525K 0.11% 241
2025
Q4 		$3.27M Sell
79,200
-42,619
-35% -$1.71M 0.11% 237
2025
Q3 		$4.73M Sell
121,819
-11,195
-8% -$364K 0.17% 145
2025
Q2 		$3.68M Sell
133,014
-51,112
-28% -$1.3M 0.15% 168
2025
Q1 		$4.09M Sell
184,126
-15,399
-8% -$317K 0.18% 138
2024
Q4 		$3.95M Buy
199,525
+3,673
+2% +$83.8K 0.18% 139
2024
Q3 		$4.89M Buy
195,852
+13,886
+8% +$338K 0.23% 100
2024
Q2 		$3.4M Buy
181,966
+57,088
+46% +$1.07M 0.17% 143
2024
Q1 		$2.46M Buy
124,878
+28,237
+29% +$551K 0.13% 213
2023
Q4 		$1.7M Buy
96,641
+41,594
+76% +$684K 0.1% 273
2023
Q3 		$956K Buy
55,047
+26,002
+90% +$438K 0.06% 366
2023
Q2 		$409K Sell
29,045
-39,836
-58% -$533K 0.02% 571
2023
Q1 		$741K Sell
68,881
-10,538
-13% -$139K 0.05% 420
2022
Q4 		$1.19M Buy
79,419
+10,041
+14% +$146K 0.07% 309
2022
Q3 		$891K Sell
69,378
-961
-1% -$10.9K 0.06% 352
2022
Q2 		$682K Sell
70,339
-1,045
-1% -$9.75K 0.04% 415
2022
Q1 		$710K Buy
71,384
+1,457
+2% +$15.4K 0.04% 431
2021
Q4 		$823K Buy
69,927
+4,368
+7% +$53.7K 0.04% 420
2021
Q3 		$747K Buy
65,559
+22,443
+52% +$292K 0.04% 416
2021
Q2 		$601K Buy
+43,116
New +$655K 0.03% 481

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Hennion & Walsh Asset Management's KNSA Position: Q2 2026 in Review

Hennion & Walsh Asset Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 67,341 shares — an estimated $3.24M sold.

Hennion & Walsh Asset Management first reported a position in KNSA in Q2 2021 and held it in 20 quarters. The position peaked at $4.89M in Q3 2024. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Hennion & Walsh Asset Management reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 67,341 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $3.24M.
  • Hennion & Walsh Asset Management first reported a position in Kiniksa Pharmaceuticals in Q2 2021 and held it in 20 quarters.
  • Hennion & Walsh Asset Management's Kiniksa Pharmaceuticals position peaked at $4.89M in Q3 2024.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.